<?xml version='1.0' encoding='utf-8'?>
<document id="17932098"><sentence text="Detecting drug interactions using personal digital assistants in an out-patient clinic." /><sentence text="The installation of drug databases on personal digital assistants (PDAs) allows for rapid detection of adverse drug interactions at the point of care" /><sentence text="" /><sentence text="To test the ability of a drug interaction database (ePocrates RX) to correctly identify clinically significant adverse drug interactions in an out-patient setting" /><sentence text="" /><sentence text="Retrospective file review of 1801 drug prescriptions in out-patients consulting a medical walk-in clinic" /><sentence text="" /><sentence text="Each prescription was assessed independently by a clinical pharmacologist using drug-drug interaction compendia, and by a general internist using the drug interaction database" /><sentence text=" Discrepant results were systematically reviewed by both, using published literature, and a consensus was then reached" /><sentence text=" This consensus was used as the criterion against which the PDA drug interaction database was judged" /><sentence text="" /><sentence text="The prevalence of potential adverse drug interactions was 23%" /><sentence text=" When compared to the opinion of the clinical pharmacologist and drug-drug interaction compedia, the sensitivity of the drug interaction database to correctly identify clinically relevant adverse drug interactions was 81% (95%CI 77%-85%) and the specificity was 88% (95%CI 86-89%)" /><sentence text=" The positive predictive value was poor (67%, 95%CI 62%-71%) but the negative predictive value was excellent (94%, 95%CI 92%-95%)" /><sentence text="" /><sentence text="The database was an efficient tool for rapidly checking for potentially harmful drug interaction, but also flagged up several clinically non-significant interactions" /><sentence text=" When used appropriately, this drug interaction database could help physicians decrease prescription error, by ruling out the risk of clinically relevant adverse drug interactions for newly prescribed drugs, and thereby increase patient safety" /><sentence text="" /></document>